Log in to save to my catalogue

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for a...

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for a...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2702975594

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Checkpoint inhibitor (CPI) therapies provide limited benefit to patients with tumors of low immune reactivity. T cell-inducing vaccines hold promise to exert long-lasting disease control in combination with CPI therapy. Safety, tolerability and recommended phase 2 dose (RP2D) of an individualized, heterologous chimpanzee adenovirus (ChAd68) and sel...

Alternative Titles

Full title

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2702975594

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2702975594

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/s41591-022-01937-6

How to access this item